科研之友
微信
新浪微博
Facebook
分享链接
摘要
Progress was made in major aspects of acute myeloid leukaemia in 2012. Gemtuzumab ozogamicin and decitabine were shown to improve outcomes, relapse after stem-cell transplantation might be prevented by selecting donors according to their KIR genotypes, and next-generation sequencing has provided insights into mutational patterns and disease evolution.Becker, H. %26 Bloomfield, C. D. Nat. Rev. Clin. Oncol. 10, 76-79 (2013); published online 8 January 2013; doi:10.1038.nrclinonc.2012.239
- 出版日期2013-2
